PT-141 (10mg Vial) Dosage Protocol

Overview

PT-141, also known as bremelanotide, is a melanocortin receptor agonist that works centrally via MC4R activation to influence sexual desire pathways. The FDA-approved formulation is intended for managing hypoactive sexual desire disorder (HSDD) in premenopausal women.

Key Specifications

Chemical Classification: Melanocortin-4 receptor (MC4R) agonist

Approved Route: Subcutaneous injection

Standard FDA-Approved Dose: “single 1.75 mg injection as needed (PRN), administered at least 45 minutes before anticipated sexual activity”

Dosing Frequency Limits: Maximum 1 dose per 24 hours; no more than 8 doses per month

Reconstitution Guide

Standard Protocol

Vial Size: 10 mg powder
Reconstitution Volume: 3.0 mL bacteriostatic water
Resulting Concentration: ~3.33 mg/mL
Measurement Method: U-100 insulin syringes (1 unit = 0.01 mL ≈ 33.3 mcg)

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water using sterile technique
2. Inject slowly down vial wall; avoid foaming
3. Gently swirl/roll until dissolved (do not shake)
4. Label and refrigerate immediately

Dosing Protocol

Administration Stage Dose (mcg) Dose (mg) Syringe Units Volume (mL)
Test Dose 500 0.50 15 units 0.15
Titration 1,000 1.00 30 units 0.30
Effective Range 1,500 1.50 45 units 0.45
Standard PRN 1,750 1.75 52.5 units 0.53

Timing Considerations

– Administer 45-60 minutes before anticipated sexual activity
– Allow at least 24 hours between doses
– Do not exceed 8 doses per month
– Reassess benefit after approximately 8 weeks of use

Storage Instructions

Lyophilized (Powder): “Cold, dark storage is commonly used for long-term stability (≤ −20 °C / ≤ −4 °F)”

Reconstituted Solution: “Refrigerate at 2–8 °C (35.6–46.4 °F) for short-term holding; avoid repeated freeze–thaw”

Shelf Life: Protect from light and moisture; minimize exposure to humidity

Supplies Needed (Per 8-Week Protocol at 1.75 mg Standard Dose)

PT-141 Vials: 4 vials (10 mg each)
U-100 Insulin Syringes: 16 syringes (single-use)
Bacteriostatic Water: 2 bottles (10 mL each)
Alcohol Swabs: 32 swabs (vial + injection site)

Note: Each 10 mg vial provides approximately 5 full standard doses

Injection Technique

Site Selection: Abdomen, thighs, or upper arms

Rotation: Systematically rotate sites to reduce local reactions and maintain consistent absorption

Injection Angle: “Insert at 45–90° into subcutaneous tissue; do not aspirate for SC injections”

Technique:
1. Clean vial stopper and skin with alcohol; allow to dry
2. Pinch a skinfold at injection site
3. Insert needle at proper angle; inject slowly and steadily
4. Do not aspirate (SC injection protocol)

Volume Tolerance: “SC injections of up to ~3.0 mL are generally well-tolerated in the abdomen”

Mechanism of Action

PT-141 activates central melanocortin receptors, “especially MC4R—in hypothalamic circuits linked to sexual desire and autonomic arousal.” Two Phase 3 RECONNECT trials demonstrated improvements in validated desire and distress measures compared to placebo using the PRN 1.75 mg subcutaneous dosing regimen.

Clinical Benefits

– Improves sexual desire and reduces related distress in premenopausal women with HSDD
– Phase 3 trial evidence supports efficacy as PRN therapy
– Supports at-home self-administration via subcutaneous delivery
– Modest appetite-suppressive effects noted in mechanistic studies under intensive dosing

Adverse Effects & Warnings

Common Adverse Effects:
– Nausea
– Flushing
– Headache
– Injection-site reactions
– Transient blood pressure increases
– Transient heart rate reductions

Important Safety Notes:
– “Exceeding labeled frequency (e.g., daily use) increased risk of focal hyperpigmentation”
– Consider cardiovascular risk factors before use
– Review full prescribing information for complete precautions
– Use new sterile syringes for each injection
– Follow aseptic preparation and disposal protocols

Lifestyle Considerations

– Communicate timing and expectations with sexual partners
– Coordinate use with anticipated sexual activity
– Support overall wellness through adequate sleep, stress management, and regular exercise
– Maintain consistent injection technique and site rotation

Last Updated: December 24, 2025
Content Type: Research Educational Material
Classification: For research reference only